Positive Phase III data for selexipag in pulmonary arterial hypertension gave Actelion Ltd. (SIX:ATLN) a CHF2.4 billion ($2.7 billion) bump in market cap, valuing the bellwether at CHF13.4 billion ($14.9 billion). Daniel Koller of BB Biotech, which holds the stock, believes Actelion now could be in a dominant position in PAH with two new drugs in different therapeutic pathways that have further combination opportunities in the long term.

On June 16, Actelion announced top-line data from